Although Eylea is approved in four indications in Europe, the label extension will only be eligible ... which licensed the rights to the drug outside the US from manufacturer Regeneron in 2012.

The wild card in the wet AMD market is off-label use of Roche’s VEGF ... Meanwhile, patents on both Lucentis and Eylea are due to expire in the US in 2020, raising the prospect of additional ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator ...

Eylea and Eylea 8mg – the latter known as Eylea HD in the US – reached combined sales of $9.5bn in 2024. Credit: OleksSH via Shutterstock. Bayer’s retinal disease treatment Eylea (aflibercept) is set ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved ...

Bayer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label extension for Eylea 8 mg ...

Bayer A.G. (OTCPK:BAYZF) (OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the label expansion of a high-dose version of its ophthalmic drug, Eylea ...

has adopted a positive opinion recommending the label extension for Eylea 8 mg (aflibercept) in the EU. This extension will enable longer treatment intervals, up to six months, for two major ...

If approved, Eylea 8 mg would become the only anti-vascular endothelial growth factor (anti-VEGF) treatment in the EU authorized for six-month intervals for both nAMD and DME, according to Bayer ...